News | March 05, 2012

Teen With Total Artificial Heart Bridged to Transplant at Texas Children’s Hospital

Jordan Merecka (right), received a new heart Oct. 29, after 160 days with a Syncardia Total Artificial Heart.

Halloween in hospital: Merecka and his surgeon, David Morales, M.D. two days after a successful transplant.

March 5, 2012 — SynCardia Systems Inc., manufacturer of the world’s first and only U.S. Food and Drug Administration (FDA), Health Canada and Conformité Européenne (CE) approved Total Artificial Heart, announced that 18-year-old Jordan Merecka was successfully bridged to a heart transplant at Texas Children’s Hospital in Houston, Texas, after 160 days of support with the SynCardia temporary Total Artificial Heart.

“Before I got the Total Artificial Heart, I had a lot of chest pain. I could only walk about 100 yards before I was out of breath and had to stop because I couldn’t go any farther,” said Jordan. “With the Total Artificial Heart, I could walk again, go outside, and I had no more chest pain. I almost felt back to my old self. Now that I have my new donor heart, it's just getting back to a normal life step by step.”

Just two days after his Oct. 29 transplant, for Halloween, Jordan masqueraded as his surgeon, David L.S. Morales, M.D. "Jordan was a little more than 24 hours out of a 12-hour surgery and he's the one cracking jokes."

Jordan made headlines in August 2011 when he became the first teen in the U.S. to be discharged from the hospital using the Freedom portable driver to power his Total Artificial Heart. Weighing 13.5 pounds, the Freedom driver is the world’s first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S. 

“It was a really good feeling getting to go home again,” said Jordan. “I’d go on little walks and go fishing with my friends. My sisters and my brother were really happy that I was back and that Mom and Dad were home so they weren’t alone all the time.”

Jordan was born with multiple congenital heart defects, including a “reversed” heart (dextrocardia) and his heart vessels backwards (corrected transposition of the great arteries). While awaiting a transplant, he was admitted to the hospital in April 2011 suffering from end-stage biventricular heart failure. The following month, his vital organs began to fail and he was placed on a ventilator. To save Jordan's life, on May 22, 2011, his doctors performed Texas Children’s first implant of the Total Artificial Heart.

For more information:

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Overlay Init